201. Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease.
- Author
-
Salman Y, Gérard T, Huyghe L, Colmant L, Quenon L, Malotaux V, Ivanoiu A, Lhommel R, Dricot L, and Hanseeuw BJ
- Subjects
- Humans, Male, Female, Aged, Hippocampus pathology, Hippocampus diagnostic imaging, Amyloid beta-Peptides metabolism, Aged, 80 and over, Neuroimaging, Temporal Lobe pathology, Temporal Lobe diagnostic imaging, Biomarkers, Alzheimer Disease pathology, Alzheimer Disease diagnostic imaging, Amygdala pathology, Amygdala diagnostic imaging, Positron-Emission Tomography, Atrophy pathology, Magnetic Resonance Imaging, tau Proteins metabolism
- Abstract
Introduction: Magnetic resonance imaging (MRI) segmentation algorithms make it possible to study detailed medial temporal lobe (MTL) substructures as hippocampal subfields and amygdala subnuclei, offering opportunities to develop biomarkers for preclinical Alzheimer's disease (AD)., Methods: We identified the MTL substructures significantly associated with tau-positron emission tomography (PET) signal in 581 non-demented individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI-3). We confirmed our results in our UCLouvain cohort including 110 non-demented individuals by comparing volumes between individuals with different visual Braak's stages and clinical diagnosis., Results: Four amygdala subnuclei (cortical, central, medial, and accessory basal) were associated with tau in amyloid beta-positive (Aβ+) clinically normal (CN) individuals, while the global amygdala and hippocampal volumes were not. Using UCLouvain data, we observed that both Braak I-II and Aβ+ CN individuals had smaller volumes in these subnuclei, while no significant difference was observed in the global structure volumes or other subfields., Conclusion: Measuring specific amygdala subnuclei, early atrophy may serve as a marker of temporal tauopathy in preclinical AD, identifying individuals at risk of progression., Highlights: Amygdala atrophy is not homogeneous in preclinical Alzheimer's disease (AD). Tau pathology is associated with atrophy of specific amygdala subnuclei, specifically, the central, medial, cortical, and accessory basal subnuclei. Hippocampal and amygdala volume is not associated with tau in preclinical AD. Hippocampus and CA1-3 volume is reduced in preclinical AD, regardless of tau., (© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
- Published
- 2024
- Full Text
- View/download PDF